Divisadero Street Capital Management LP Buys Shares of 48,220 MiMedx Group, Inc. (NASDAQ:MDXG)

Divisadero Street Capital Management LP bought a new position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 48,220 shares of the company's stock, valued at approximately $464,000.

Several other hedge funds also recently modified their holdings of the company. Cannell Capital LLC lifted its stake in MiMedx Group by 1.1% during the fourth quarter. Cannell Capital LLC now owns 3,639,545 shares of the company's stock valued at $35,012,000 after purchasing an additional 40,235 shares during the last quarter. First Light Asset Management LLC acquired a new stake in MiMedx Group during the fourth quarter valued at $32,168,000. Renaissance Technologies LLC lifted its stake in shares of MiMedx Group by 18.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock valued at $17,360,000 after purchasing an additional 280,327 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in MiMedx Group by 15.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company's stock worth $17,338,000 after purchasing an additional 238,075 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in MiMedx Group by 11.4% during the fourth quarter. Northern Trust Corp now owns 1,199,970 shares of the company's stock valued at $11,544,000 after acquiring an additional 123,205 shares during the period. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MDXG has been the topic of several recent research reports. StockNews.com lowered MiMedx Group from a "strong-buy" rating to a "buy" rating in a report on Friday. Cantor Fitzgerald reissued an "overweight" rating and set a $13.00 price objective on shares of MiMedx Group in a report on Thursday, February 27th.

Insider Buying and Selling at MiMedx Group

In other MiMedx Group news, CAO William Frank Iv Hulse sold 54,596 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the transaction, the chief accounting officer now owns 440,178 shares in the company, valued at $3,473,004.42. This trade represents a 11.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Joseph H. Capper bought 200,000 shares of the firm's stock in a transaction on Friday, May 2nd. The shares were acquired at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the transaction, the chief executive officer now owns 529,530 shares in the company, valued at approximately $3,357,220.20. This represents a 60.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 144,018 shares of company stock worth $1,130,312 over the last quarter. 1.30% of the stock is currently owned by insiders.

MiMedx Group Trading Up 2.2%

Shares of NASDAQ MDXG traded up $0.16 during midday trading on Monday, reaching $7.21. 372,839 shares of the stock were exchanged, compared to its average volume of 694,219. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of 13.11 and a beta of 1.85. The business has a 50-day simple moving average of $7.28 and a two-hundred day simple moving average of $8.15.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. The company had revenue of $88.21 million during the quarter, compared to analysts' expectations of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. As a group, equities research analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current year.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.